دورية أكاديمية
أعرض في EDS

Molecular Investigation of the Antitumor Effects of Monoamine Oxidase Inhibitors in Breast Cancer Cells.

التفاصيل البيبلوغرافية
العنوان: Molecular Investigation of the Antitumor Effects of Monoamine Oxidase Inhibitors in Breast Cancer Cells.
المؤلفون: Alkhawaldeh A; Department of Pharmaceutical Sciences, School of Pharmacy, University of Jordan, Queen Rania Street, Amman 11942, Jordan., Bardaweel S; Department of Pharmaceutical Sciences, School of Pharmacy, University of Jordan, Queen Rania Street, Amman 11942, Jordan.
المصدر: BioMed research international [Biomed Res Int] 2023 Oct 05; Vol. 2023, pp. 2592691. Date of Electronic Publication: 2023 Oct 05 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Hindawi Pub. Co Country of Publication: United States NLM ID: 101600173 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York, NY : Hindawi Pub. Co.
مواضيع طبية MeSH: Monoamine Oxidase Inhibitors*/pharmacology , Breast Neoplasms*/drug therapy , Breast Neoplasms*/genetics, Male ; Humans ; Monoamine Oxidase/genetics ; Monoamine Oxidase/metabolism ; Oxidative Stress ; Reactive Oxygen Species/metabolism
مستخلص: The catalytic activity of monoamine oxidase A (MAO-A) has been linked to tumorigenesis due to the production of reactive oxygen species (ROS) and the resulting oxidative stress. MAO-A inhibition revealed a beneficial role in prostate and lung cancer treatment. This study is aimed at evaluating the effect of different monoamine oxidase A inhibitors (MAO-AIs) on the proliferation and progression of breast cancer cell lines. The cell viability assay was used to evaluate the antiproliferative and combined effects of MAO-AIs. Cell migration was evaluated using wound healing, invasion, and colony formation assays. The underlying mechanism of cell death was studied using flow cytometry. The real-time polymerase chain reaction was used to determine the relative gene expression. Finally, MAO-A activity in breast cancer cells was evaluated using an MAO-A activity assay. According to the results, the examined MAO-AIs significantly inhibited the proliferation of breast cancer cells in a dose-dependent manner. In breast cancer cells, the combination of anticancer drugs (doxorubicin or raloxifene) with MAO-AIs resulted in a synergistic effect. MAO-AIs significantly reduced wound closure and invasion ability in breast cancer cells. Also, MAO-AIs reduced the colony count and size of breast cancer cells. MAO-AIs resulted in significant proapoptotic activity in breast cancer cells. Finally, the MAO-AIs suppressed MAO-A , Bcl-2 , and VEGF gene expressions in breast cancer cells relative to untreated cells. This study provides solid evidence supporting the anticancer effect of MAO-A inhibitors in breast cancer cells.
Competing Interests: The authors declare no conflict of interest.
(Copyright © 2023 Aseel Alkhawaldeh and Sanaa Bardaweel.)
References: Cancer Med. 2020 Nov;9(21):8004-8019. (PMID: 32931665)
Oncogene. 2018 Sep;37(38):5175-5190. (PMID: 29844571)
Prostate. 2019 May;79(6):667-677. (PMID: 30693539)
Anticancer Agents Med Chem. 2022;22(18):3114-3124. (PMID: 35473535)
Cell Signal. 2014 Dec;26(12):2621-32. (PMID: 25152370)
J Clin Invest. 2014 Jul;124(7):2891-908. (PMID: 24865426)
Cell Mol Biol Lett. 2019 Nov 12;24:59. (PMID: 31754354)
Cold Spring Harb Perspect Med. 2016 Mar 01;6(3):a026104. (PMID: 26931810)
Hypertension. 2013 Jul;62(1):140-6. (PMID: 23670301)
Curr Med Chem. 2009;16(25):3267-85. (PMID: 19548866)
J Hepatol. 2014 Jun;60(6):1225-34. (PMID: 24607627)
Sci Rep. 2019 Jul 29;9(1):10989. (PMID: 31358840)
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:102-11. (PMID: 24104186)
Eurasian J Med. 2018 Oct;50(3):193-201. (PMID: 30515042)
J Neural Transm (Vienna). 2018 Nov;125(11):1553-1566. (PMID: 30259128)
Int J Biol Sci. 2020 Aug 1;16(14):2692-2703. (PMID: 32792865)
J Pathol. 2017 Oct;243(2):220-229. (PMID: 28722111)
Int J Mol Sci. 2017 Dec 20;18(12):. (PMID: 29261141)
Tumour Biol. 2014 Nov;35(11):10635-44. (PMID: 25238879)
Expert Opin Ther Targets. 2017 Oct;21(10):959-966. (PMID: 28831824)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Pharmaceutics. 2011 Mar 11;3(1):107-24. (PMID: 24310428)
Acta Pharm. 2020 Jun 1;70(2):179-190. (PMID: 31955147)
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jul 1;44:118-24. (PMID: 23410524)
Molecules. 2020 Dec 25;26(1):. (PMID: 33375766)
Antimicrob Agents Chemother. 2012 Mar;56(3):1508-15. (PMID: 22203607)
Molecules. 2022 Apr 30;27(9):. (PMID: 35566238)
Nat Clin Pract Oncol. 2007 Mar;4(3):181-9. (PMID: 17327858)
Molecules. 2021 Oct 04;26(19):. (PMID: 34641563)
BMC Med Genomics. 2009 Aug 20;2:55. (PMID: 19691856)
Curr Opin Pharmacol. 2017 Apr;33:64-69. (PMID: 28528298)
Molecules. 2020 May 11;25(9):. (PMID: 32403270)
J Mol Cell Cardiol. 2014 Aug;73:34-42. (PMID: 24412580)
J Urol. 2008 Nov;180(5):2206-11. (PMID: 18804811)
Cancer Res. 1996 May 1;56(9):2013-6. (PMID: 8616842)
Cancer Res. 2010 Jan 15;70(2):440-6. (PMID: 20068163)
CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525)
BMC Complement Altern Med. 2014 Aug 12;14:297. (PMID: 25112895)
Oncol Lett. 2018 Mar;15(3):3245-3251. (PMID: 29435065)
Adv Hematol. 2012;2012:524308. (PMID: 21941553)
Nat Commun. 2020 Jun 1;11(1):2689. (PMID: 32483206)
Oncotarget. 2016 Mar 22;7(12):13842-53. (PMID: 26871599)
PLoS One. 2014 Sep 08;9(9):e104271. (PMID: 25198178)
Int J Breast Cancer. 2011;2011:967419. (PMID: 22332018)
Sci Rep. 2016 Feb 24;6:21986. (PMID: 26906215)
المشرفين على المادة: 0 (Monoamine Oxidase Inhibitors)
EC 1.4.3.4 (Monoamine Oxidase)
0 (Reactive Oxygen Species)
تواريخ الأحداث: Date Created: 20231016 Date Completed: 20231023 Latest Revision: 20231023
رمز التحديث: 20231023
مُعرف محوري في PubMed: PMC10569896
DOI: 10.1155/2023/2592691
PMID: 37841082
قاعدة البيانات: MEDLINE
الوصف
تدمد:2314-6141
DOI:10.1155/2023/2592691